ArticleNeoplasia (New York, N.Y.)2007
Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody.
Article in Neoplasia (New York, N.Y.), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 74 citations in OpenAlex.
- Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.Neuro-oncology · 2023Trial
- A novel miniaturized filamentous phagemid as a gene delivery vehicle to target mammalian cells.Molecular therapy. Nucleic acids · 2025Article
- Antibody Format and Serum Disposition Govern Ocular Pharmacokinetics of Intravenously Administered Protein Therapeutics.Frontiers in pharmacology · 2021Article
- Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism.International journal of clinical oncology · 2020Article
- Image-guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer.Oncotarget · 2019Article
- The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans.EJNMMI research · 2019Article
- Article
- Article
- Impact of assay temperature on antibody binding characteristics in living cells: A case study.Biomedical reports · 2017Article
- Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture ComponentsIranian biomedical journal · 2017Review
- A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.Seminars in oncology · 2017Review
- Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.Oncoimmunology · 2016Article
- High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe.Journal of biomolecular screening · 2016Article
- Synthetically Modified Viral Capsids as Versatile Carriers for Use in Antibody-Based Cell Targeting.Bioconjugate chemistry · 2015Article
- Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.Drug metabolism and disposition: the biological fate of chemicals · 2014Article
- A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA.Molecular therapy. Nucleic acids · 2014Article
- Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy.Pharmaceuticals (Basel, Switzerland) · 2014Article
- A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.Cancer biology & therapy · 2014Article
- Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Pharmacology & therapeutics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of the epidermal growth factor receptor (EGFR) in epithelial tumors is associated with poor prognosis and is the target for a number of cancer therapeutics. Monoclonal antibody (mAb) 806 is a novel anti-EGFR antibody with significant therapeutic efficacy in tumor models when used as a single agent, and displays synergistic antitumor activity in combination with other EGFR therapeutics. Unlike other EGFR antibodies, mAb 806 is selective for tumor cells and does not bind to normal tissue, making it an ideal candidate for generation of radioisotope or toxin conjugates. Ideally, antibodies suited to these therapeutic applications must bind to and actively internalize their cognate receptor. We investigated the intracellular trafficking of fluorescently tagged mAb 806 in live cells and analyzed its biodistribution in a tumor xenografted nude mouse model. Following binding to EGFR, mAb 806 was internalized through dynamin-dependent, clathrin-mediated endocytosis. Internalized mAb 806 localized to early endosomes and subsequently trafficked to and accumulation in lysosomal compartments. Furthermore, biodistribution analysis in nude mice showed specific uptake and retention of radiolabeled mAb 806 to human tumor xenografts. These results highlight the potential use of mAb 806 for generation of conjugates suitable for diagnostic and therapeutic use in patients with EGFR-positive malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.